/home/corante/public_html/pipeline/ en-us derekb.lowe@gmail.com 2013-05-14T07:47:06-05:00 hourly 1 2000-01-01T12:00+00:00 http://pipeline.corante.com/archives/2013/05/14/a_specific_crowdfunding_example.php I mentioned Microryza in that last post. Here's Prof. Michael Pirrung, at UC Riverside, with an appeal there to fund the resynthesis of a compound for NCI testing against renal cell carcinoma. It will provide an experienced post-doc's labor for... 76415@/home/corante/public_html/pipeline/ Cancer 2013-05-14T07:47:06-05:00 http://pipeline.corante.com/archives/2013/05/06/the_medical_periodic_table.php Here's the latest "medical periodic table", courtesy of this useful review in Chemical Communications. Element symbols in white are known to be essential in man. The ones with a blue background are found in the structures of known drugs, the... 76390@/home/corante/public_html/pipeline/ Odd Elements in Drugs 2013-05-06T06:44:29-05:00 http://pipeline.corante.com/archives/2013/05/02/aveo_gets_bad_news_on_tivozanib.php The kinase inhibitor tivozanib (for renal cell carcinoma) was shot down this morning at an FDA committee hearing. There are going to be a lot of arguments about this decision, because feelings have been running high on both sides of... 76386@/home/corante/public_html/pipeline/ Cancer 2013-05-02T11:18:39-05:00 http://pipeline.corante.com/archives/2013/04/29/costing_just_too_much.php There's been a lot of rumbling recently about the price of new cancer drugs (see this article for a very typical reaction). It's a topic that's come up around here many times, as would be only natural - scrolling back... 76376@/home/corante/public_html/pipeline/ Drug Prices 2013-04-29T12:44:48-05:00 http://pipeline.corante.com/archives/2013/04/24/watching_parp1_inhibitors_fail_to_work_cell_by_cell.php Here's something that's been sort of a dream of medicinal chemists and pharmacologists, and now can begin to be realized: single-cell pharmacokinetics. For those outside the field, you should know that we spend a lot of time on our drug... 76364@/home/corante/public_html/pipeline/ Pharmacokinetics 2013-04-24T06:32:13-05:00 http://pipeline.corante.com/archives/2013/04/22/cancer_back_to_nofone.php From Nature comes this news of an effort to go back to oncology clinical trials and look at the outliers: the people who actually showed great responses to otherwise failed drugs. By all rights, Gerald Batist’s patient should have died... 76358@/home/corante/public_html/pipeline/ Cancer 2013-04-22T10:37:20-05:00 http://pipeline.corante.com/archives/2013/04/18/superenhancers_in_cell_biology_encodes_revenge.php I've linked to some very skeptical takes on the ENCODE project, the effort that supposedly identified 80% of our DNA sequence as functional to some degree. I should present some evidence for the other side, though, as it comes up,... 76351@/home/corante/public_html/pipeline/ Biological News 2013-04-18T07:29:21-05:00 http://pipeline.corante.com/archives/2013/04/02/stealing_a_compound_to_set_up_in_china.php Here's a strange case worth keeping an eye on. Via Deborah Blum's Twitter feed we have this report of a researcher in Wisconsin being charged with economic espionage - specifically, investigational oncology. Huajun Zhao, 42, faces a single count of... 76321@/home/corante/public_html/pipeline/ Cancer 2013-04-02T11:32:29-05:00 http://pipeline.corante.com/archives/2013/04/01/novartis_loses_the_glivec_patent_fight_in_india.php This story is all over the news today, but it's my impression that most of the stories leave out crucial details. This is not just a big multinational drug company being put in its place by Indian courts, nor is... 76317@/home/corante/public_html/pipeline/ Patents and IP 2013-04-01T11:20:55-05:00 http://pipeline.corante.com/archives/2013/03/27/a_therapy_named_after_you.php Back last fall I wrote about Prof. Magnus Essand and his oncoloytic virus research. He's gotten a good amount of press coverage, and has been trying all sorts of approaches to get further work funded. But here's one that I... 76308@/home/corante/public_html/pipeline/ Cancer 2013-03-27T11:11:43-05:00 http://pipeline.corante.com/archives/2013/03/25/james_watson_likes_us_anyway.php Around us we see changes in everything, but there are some constants that we can count on. James Watson, for example, is still James Watson: While noting that genetics is vital, Watson said, "You could sequence 150,000 people with cancer... 76300@/home/corante/public_html/pipeline/ Cancer 2013-03-25T06:54:14-05:00 http://pipeline.corante.com/archives/2013/03/22/good_news_in_oncology_more_immune_therapy_for_leukemia.php I've written a couple of times about the work at the University of Pennsylvania on modified T-cell therapy for leukemia (CLL). Now comes word that a different version of this approach seems to be working at Sloan-Kettering. Recurrent B-cell acute... 76296@/home/corante/public_html/pipeline/ Biological News 2013-03-22T07:06:43-05:00 http://pipeline.corante.com/archives/2013/03/22/good_news_in_oncology_oncolytic_virus_therapy.php The last few days have brought some good news on some unusual approaches to cancer therapy. First off was Amgen's report that they'd seen positive results in advanced melanoma using a modified HSV treatment. This is technology that they brought... 76295@/home/corante/public_html/pipeline/ Cancer 2013-03-22T06:12:17-05:00 http://pipeline.corante.com/archives/2013/02/15/abt199_clinical_trial_suspended_updated.php Abbott - whoops, pardon me, I mean AbbVie, damn that name - has been developing ABT-199, a selective Bcl-2-targeted oncology compound for CLL. Unlike some earlier shots in this area (ABT-263, navitoclax), it appeared to spare platelet function, and was... 76215@/home/corante/public_html/pipeline/ Cancer 2013-02-15T08:05:23-05:00 http://pipeline.corante.com/archives/2013/01/28/time_to_refill_your_prescription_for_zxygjfb.php The brand names of drugs are famously odd. But they seem to be getting odder. That's the conclusion of a longtime reader, who sent this along: I was recently perusing through the recent drug approval list and was struck by... 76166@/home/corante/public_html/pipeline/ Business and Markets 2013-01-28T08:14:50-05:00